Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
P/E ratio for Mind Medicine (MindMed) Inc. (MNMD)
P/E ratio as of 2023: -1.50
According to Mind Medicine (MindMed) Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.50. At the end of 2022 the company had a P/E ratio of -1.44.
P/E ratio history for Mind Medicine (MindMed) Inc. from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.50 |
| 2022 | -1.44 |
| 2021 | -6.09 |
| 2020 | -23.81 |
| 2019 | -0.24 |
| 2018 | -0.55 |
| 2017 | -1.17 |
| 2016 | -1.51 |
| 2015 | -2.88 |